Latest Content

Renaming borderline personality disorder fails to address the condition's complexity; keeping the term preserves key clinical meaning, including structural traits and stress-related psychotic symptoms.

Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.

Get real-time psychiatry conference highlights with video interviews, session takeaways, and quick clips from APA and psychopharmacology meetings.

Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.

New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.